Back to results
US 2003/0198643 A1Published application
Adjuvant enhanced immunotherapy
OwnerYingjuan Luinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerYingjuan Luinventor
Estimating the term…
An improved method is provided for treating disease states characterized by the existence of pathogenic cell populations. In accordance with the improved method, cell-targeted ligand-immunogen or ligand-hapten complexes are administered to a diseased host to redirect the host immune response to the pathogenic cells which have an accessible binding site for the ligand. The method comprises the step of administering to the host a ligand-immunogen or ligand-hapten conjugate composition comprising a complex of the ligand and the immunogen or hapten wherein the immunogen/hapten is recognized by an endogenous antibody in the host or directly by an immune cell in the host. The improvement to the method comprises the step of using a TH1-biasing adjuvant to enhance the immune response to cell-bound ligand-immunogen or ligand-hapten conjugates.
In a method of enhancing an endogenous immune response-mediated specific elimination of a population of pathogenic cells in a preimmunized host animal harboring the population wherein the members of the cell population have an accessible binding site for a ligand, and wherein the method comprises the step of administering to the host a composition comprising an immunogen or a hapten conjugated to the ligand wherein the immunogen or hapten is recognized by an endogenous antibody in the host or is recognized directly by an immune cell in the host, the improvement comprising the step of preimmunizing the host with the immunogen or an immunogenic hapten-carrier conjugate and a TH1-biasing adjuvant to elicit a preexisting immunity.
A method of enhancing an immune response in a host animal harboring a population of pathogenic cells to eliminate said pathogenic cell population wherein the pathogenic cells have an accessible binding site for a ligand, said method comprising the steps of
A composition comprising therapeutically effective amounts of a TH1-biasing adjuvant and a hapten-carrier conjugate wherein the hapten is selected from the group consisting of fluorescein and dinitrophenyl.
A composition comprising therapeutically effective amounts of a TH1-biasing adjuvant and a ligand-immunogen conjugate.
A kit comprising a TH1-biasing adjuvant and a hapten-carrier conjugate wherein the hapten is selected from the group consisting of fluorescein and dinitrophenyl.
A kit comprising a TH1-biasing adjuvant, a hapten-carrier conjugate, and a ligand-hapten conjugate.
A kit comprising a TH1-biasing adjuvant and a ligand-immunogen conjugate.
A kit comprising a TH1-biasing adjuvant, an immunogen, and a ligand-immunogen conjugate.
Dependencies are inferred from the claim text.